Sanford Health Enters Partnership with Congenica to Provide Answers for Undiagnosed Rare Disease Patients

Rare Daily Staff

Healthcare provider Sanford Health digital health company Congenica have entered a genomics partnership focused on providing answers for patients and families with hard to diagnose rare diseases.

Congenica’s rapid genomic data analysis software can interpret whole genomes in minutes to help drive down the turnaround time for getting actionable information for patients to only a matter of weeks. As a result, the company said parents can avoid an agonizing diagnostic odyssey of repeatedly going to different specialists, and patient outcomes can be significantly improved.

Sanford Health is one of the largest health systems in the United States. It has an integrated delivery network of healthcare services and a focus on genomic medicine. Sanford will use Congenica’s decision support platform to analyze and interpret patient genomes to provide information that can be used by clinicians in identifying the underlying causes of previously undiagnosed rare diseases. The expectation is that the partnership will enable previously undiagnosed patients to receive the appropriate clinical care and therapy and improve outcomes.

“This partnership between Congenica and Sanford has the potential to have a transformational impact on clinical outcomes for rare disease patients,” said David Pearce, president of Innovation, Research, and World Clinics at Sanford Health. “We selected Congenica for this project as its platform has the capability of generating rapid and accurate analysis for patients who are currently the hardest to diagnose.”

Photo: David Pearce, president of Innovation, Research, and World Clinics at Sanford Health.